Continuous glucose monitoring offers many benefits to the families of young children with type 1 diabetes but also a number of challenges that cannot always be overcome, show results of a qualitative analysis conducted in the USA.
Most hypoglycemia outcomes measured by real-time continuous glucose monitoring can be used to predict future severe hypoglycemia in people with type 1 diabetes, with similar levels of accuracy, study findings indicate.
Even with newer devices, continuous glucose monitoring underestimates the fall in glucose levels during exercise, with the drop lagging significantly behind that measured by self-monitoring of blood glucose, research shows.
People with type 1 diabetes at high hypoglycemia risk using insulin pumps have fewer hypoglycemic events if the pump is linked to a continuous glucose monitor and has a suspend-before-low feature, SMILE study data show.
The frequency at which people with type 1 diabetes experience hypoglycemia decreases during the first 30 days after they switch to a continuous glucose monitor that incorporates a predictive low-glucose alert, research shows.
Baseline data from the WISDM trial show that older adults with type 1 diabetes who have impaired awareness of hypoglycemia symptoms can spend over half an hour per day with extremely low blood glucose levels.
Giving children continuous glucose monitoring from the point of diabetes diagnosis gives their caregivers greater confidence to manage hypoglycemia and reduces their diabetes-related distress, shows a randomized trial.
A prespecified analysis of the CONCEPTT trial shows that pregnant women with type 1 diabetes who were using pumps at baseline did not achieve as good glycemic control as those using multiple daily injections.
The Tandem Basal-IQ predictive low-glucose suspend insulin delivery system significantly reduces the proportion of time adults and children spend in hypoglycemia during 24-hour usage, show findings from the randomized crossover PROLOG trial.